Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Viridian Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
VRDN
Nasdaq
8731
https://www.viridiantherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Viridian Therapeutics Inc
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 4th, 2024 8:01 pm
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
- Mar 5th, 2024 1:00 pm
Viridian Therapeutics Full Year 2023 Earnings: Misses Expectations
- Feb 29th, 2024 10:25 am
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
- Feb 27th, 2024 9:01 pm
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
- Feb 16th, 2024 1:00 pm
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
- Jan 18th, 2024 3:00 am
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
- Jan 17th, 2024 9:01 pm
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
- Jan 8th, 2024 1:00 pm
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 4th, 2024 1:00 pm
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease
- Dec 18th, 2023 12:00 pm
Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
- Nov 21st, 2023 1:00 pm
Viridian Therapeutics Inc (VRDN) Reports Q3 2023 Financial Results and Corporate Progress
- Nov 13th, 2023 10:00 pm
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 13th, 2023 9:01 pm
Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference
- Nov 8th, 2023 1:00 pm
Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology
- Nov 3rd, 2023 12:00 pm
Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing
- Oct 30th, 2023 12:30 pm
Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease
- Oct 26th, 2023 12:00 pm
Insider Traders Lose US$114k As Viridian Therapeutics Drops
- Sep 25th, 2023 3:00 pm
Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors
- Sep 25th, 2023 12:00 pm
Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September
- Sep 7th, 2023 12:00 pm
Scroll